Prot# IRUSIRES0420/NU C05N2: Phase II Study of Skin Toxicity Dosing of IRESSA® (gefitinib) as Monotherapy in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Project: Research project

Project Details

StatusFinished
Effective start/end date11/27/06 → 4/30/14

Funding

  • The University of Chicago (IRUSIRES0420/NU C05N2 // IRUSIRES0420/NU C05N2)
  • AstraZeneca Pharmaceuticals LP (IRUSIRES0420/NU C05N2 // IRUSIRES0420/NU C05N2)